Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Home
Authors
Posts by Tess Egginton
Tess Egginton
1400 POSTS
0 COMMENTS
http://www.pbiforum.net
CohBar and Morphogenesis enter into definitive merger agreement to advance an...
25th May 2023
Braeburn’s BRIXADI extended-release injection receives FDA approval for opioid use disorder
25th May 2023
Akebia receives UK MHRA approval for Vafseo for symptomatic anemia associated...
24th May 2023
U.S. FDA approves Indivior’s nasal spray for opioid overdose rescue
24th May 2023
Centessa Pharmaceuticals receives Fast Track designation from the U.S. FDA for...
24th May 2023
Ironwood enters into definitive agreement to acquire VectivBio
23rd May 2023
AVROBIO agrees to sell cystinosis gene therapy program to Novartis for...
23rd May 2023
FDA approves Bausch + Lomb and Novaliq’s MIEBO to treat signs...
22nd May 2023
EPKINLY approved by U.S. FDA as the first bispecific antibody to...
22nd May 2023
UK makes £39m cash injection into AMR research
22nd May 2023
1
...
76
77
78
...
140
Page 77 of 140
News
AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies
14th February 2025
AbbVie and Xilio Therapeutics, a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, have announced a collaboration and...
Duchenne muscular dystrophy market to reach $5.2 billion in 7MM by 2033, forecasts GlobalData
14th February 2025
The Duchenne muscular dystrophy (DMD) market across the seven major markets (7MM*) is set to grow from $2.3 billion in 2023 to $5.2 billion...
Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration
13th February 2025
Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a...